150 related articles for article (PubMed ID: 12187506)
1. Prevalence of HIV protease mutations on failure of nelfinavir-containing HAART: a retrospective analysis of four clinical studies and two observational cohorts.
Clotet B; Ruiz L; Martinez-Picado J; Negredo E; Hill A; Popescu M
HIV Clin Trials; 2002; 3(4):316-23. PubMed ID: 12187506
[TBL] [Abstract][Full Text] [Related]
2. Drug resistance mutations and outcome of second-line treatment in patients with first-line protease inhibitor failure on nelfinavir-containing HAART.
Røge BT; Katzenstein TL; Nielsen HL; Gerstoft J
HIV Med; 2003 Jan; 4(1):38-47. PubMed ID: 12534958
[TBL] [Abstract][Full Text] [Related]
3. HIV-1 genotypes related to failure of nelfinavir as the first protease inhibitor treatment.
Tupinambás U; Aleixo A; Greco D
Braz J Infect Dis; 2005 Aug; 9(4):324-9. PubMed ID: 16270125
[TBL] [Abstract][Full Text] [Related]
4. Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments.
Garriga C; Pérez-Elías MJ; Delgado R; Ruiz L; Nájera R; Pumarola T; Alonso-Socas Mdel M; García-Bujalance S; Menéndez-Arias L;
J Med Virol; 2007 Nov; 79(11):1617-28. PubMed ID: 17854027
[TBL] [Abstract][Full Text] [Related]
5. Diverse pattern of protease inhibitor resistance mutations in HIV-1 infected patients failing nelfinavir.
Svedhem V; Lindkvist A; Bergroth T; Knut L; Sönnerborg A
J Med Virol; 2005 Aug; 76(4):447-51. PubMed ID: 15977242
[TBL] [Abstract][Full Text] [Related]
6. N88D facilitates the co-occurrence of D30N and L90M and the development of multidrug resistance in HIV type 1 protease following nelfinavir treatment failure.
Mitsuya Y; Winters MA; Fessel WJ; Rhee SY; Hurley L; Horberg M; Schiffer CA; Zolopa AR; Shafer RW
AIDS Res Hum Retroviruses; 2006 Dec; 22(12):1300-5. PubMed ID: 17209774
[TBL] [Abstract][Full Text] [Related]
7. Virologic response to nelfinavir-based regimens: pharmacokinetics and drug resistance mutations (VIRAPHAR study).
Pellegrin I; Breilh D; Montestruc F; Caumont A; Garrigue I; Morlat P; Le Camus C; Saux MC; Fleury HJ; Pellegrin JL
AIDS; 2002 Jul; 16(10):1331-40. PubMed ID: 12131209
[TBL] [Abstract][Full Text] [Related]
8. Phenotypic cross-resistance to nelfinavir: the role of prior antiretroviral therapy and the number of mutations in the protease gene.
Dronda F; Casado JL; Moreno S; Hertogs K; García-Arata I; Antela A; Pérez-Elías MJ; Ruiz L; Larder B;
AIDS Res Hum Retroviruses; 2001 Feb; 17(3):211-5. PubMed ID: 11177403
[TBL] [Abstract][Full Text] [Related]
9. Molecular analysis of the HIV-1 resistance development: enzymatic activities, crystal structures, and thermodynamics of nelfinavir-resistant HIV protease mutants.
Kozísek M; Bray J; Rezácová P; Sasková K; Brynda J; Pokorná J; Mammano F; Rulísek L; Konvalinka J
J Mol Biol; 2007 Dec; 374(4):1005-16. PubMed ID: 17977555
[TBL] [Abstract][Full Text] [Related]
10. Resistance mutations in HIV-infected patients experiencing early failure with nelfinavir-containing triple combinations.
Núńez M; de Mendoza C; Valer L; Casas E; López-Calvo S; Castro A; Rosón B; Podzamczer D; Rubio A; Berenguer J; Soriano V
Med Sci Monit; 2002 Sep; 8(9):CR620-3. PubMed ID: 12218942
[TBL] [Abstract][Full Text] [Related]
11. [HIV genotypic mutation selectively induced by the protease inhibitor nelfinavir at codon 30. Case series and consequences for antiretroviral management].
Manfredi R; Calza L
Infez Med; 2002 Sep; 10(3):151-6. PubMed ID: 12704265
[TBL] [Abstract][Full Text] [Related]
12. Interference between D30N and L90M in selection and development of protease inhibitor-resistant human immunodeficiency virus type 1.
Sugiura W; Matsuda Z; Yokomaku Y; Hertogs K; Larder B; Oishi T; Okano A; Shiino T; Tatsumi M; Matsuda M; Abumi H; Takata N; Shirahata S; Yamada K; Yoshikura H; Nagai Y
Antimicrob Agents Chemother; 2002 Mar; 46(3):708-15. PubMed ID: 11850252
[TBL] [Abstract][Full Text] [Related]
13. Emergence of drug resistance mutations in a group of HIV-infected children taking nelfinavir-containing regimens.
Fitzgibbon JE; Gaur S; Walsman SM; Janahi M; Whitley-Williams P; John JF
AIDS Res Hum Retroviruses; 2001 Sep; 17(14):1321-8. PubMed ID: 11602042
[TBL] [Abstract][Full Text] [Related]
14. Impact of human immunodeficiency virus type 1 subtype C on drug resistance mutations in patients from Botswana failing a nelfinavir-containing regimen.
Doualla-Bell F; Avalos A; Gaolathe T; Mine M; Gaseitsiwe S; Ndwapi N; Novitsky VA; Brenner B; Oliveira M; Moisi D; Moffat H; Thior I; Essex M; Wainberg MA
Antimicrob Agents Chemother; 2006 Jun; 50(6):2210-3. PubMed ID: 16723586
[TBL] [Abstract][Full Text] [Related]
15. Resistance testing in children changing human immunodeficiency virus type 1 protease inhibitor.
Servais J; Hainaut M; Schmitz V; Maes P; Fransen K; Vaira D; Brichard B; Arendt V; Schneider F; Hemmer R; Schmit JC
Pediatr Infect Dis J; 2002 Mar; 21(3):214-20. PubMed ID: 12005085
[TBL] [Abstract][Full Text] [Related]
16. Mutation D30N is not preferentially selected by human immunodeficiency virus type 1 subtype C in the development of resistance to nelfinavir.
Grossman Z; Paxinos EE; Averbuch D; Maayan S; Parkin NT; Engelhard D; Lorber M; Istomin V; Shaked Y; Mendelson E; Ram D; Petropoulos CJ; Schapiro JM
Antimicrob Agents Chemother; 2004 Jun; 48(6):2159-65. PubMed ID: 15155216
[TBL] [Abstract][Full Text] [Related]
17. Evolution of primary protease inhibitor resistance mutations during protease inhibitor salvage therapy.
Kantor R; Fessel WJ; Zolopa AR; Israelski D; Shulman N; Montoya JG; Harbour M; Schapiro JM; Shafer RW
Antimicrob Agents Chemother; 2002 Apr; 46(4):1086-92. PubMed ID: 11897594
[TBL] [Abstract][Full Text] [Related]
18. The influence of protease inhibitor resistance profiles on selection of HIV therapy in treatment-naive patients.
Turner D; Schapiro JM; Brenner BG; Wainberg MA
Antivir Ther; 2004 Jun; 9(3):301-14. PubMed ID: 15259893
[TBL] [Abstract][Full Text] [Related]
19. Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors.
Ntemgwa M; Brenner BG; Oliveira M; Moisi D; Wainberg MA
Antimicrob Agents Chemother; 2007 Feb; 51(2):604-10. PubMed ID: 17116674
[TBL] [Abstract][Full Text] [Related]
20. Persistence of mutations during replication of an HIV library containing combinations of selected protease mutations.
Song W; Maeda Y; Tenpaku A; Harada S; Yusa K
Antiviral Res; 2004 Mar; 61(3):173-80. PubMed ID: 15168798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]